Margin of Insight
← Free primer

Investment Memorandum · Preview

For informational purposes only. Not investment advice.

Lam Research

LRCX

UNFAVORABLE

May 26, 2026

Research Conclusion

Lam Research is a world-class semiconductor capital equipment franchise with ROIC 30%+ through-cycle, an elite CSBG recurring revenue engine approaching $8B/year, and unique technology positioning in HBM etch. At $276/share (38x forward P/E), the stock prices in the HBM secular supercycle scenario with minimal margin for error. Probability-weighted fair value is ~$208, implying 25% downside in expected value terms.

Company Overview & Moat Assessment

Lam Research (NASDAQ: LRCX) is one of four dominant global semiconductor capital equipment suppliers, specializing in etch and deposition. Generated ~$16.4B in FY2025 revenue: 65% from new equipment systems, 35% from CSBG (customer support and global services) aftermarket business. Holds #1 or #2 market share in virtually every etch and deposition sub-segment. Installed base across thousands of customer fabs creates durable, growing service revenue annuity. With ~$345B market cap and ~1.25B diluted shares, ranks third-largest semiconductor equipment company globally behind ASML and AMAT.

▲ Bull Case

  • ◆HBM4 supercycle creates structurally higher etch intensity floor: 16-layer HBM4 requires ~5x TSV etch steps vs. standard DRAM, permanently raising etch content per chip; FY2028 HBM systems revenue could exceed $5B; FY28 EPS $9.50 at 32x = $304
  • ◆CSBG approaching $8-10B is standalone recurring business worth 25-30x earnings, currently priced at cyclical multiples; as CSBG reaches 40-45% of revenue, blended multiple re-rates upward structurally, adding $30-50/share to fair value
  • ◆NAND $40B upgrade cycle in Korea/Japan/US provides independent 2-3 year revenue tailwind for QCNAND and 200+ layer structures, not dependent on HBM demand

▼ Bear Case

  • ◆38x P/E prices in 7+ years of above-average growth — historically unrealistic for SEMCAP; WFE has never sustained $130B+ for more than 2-3 years before cyclical reversion; bear case EPS $6.50 × 22x = $143, a $133 drawdown
  • ◆China regulatory risk is asymmetric: represents 32-34% of revenue; each BIS restriction round permanently reduces China revenue without replacement; moderate new restrictions could reduce revenue by $2-3B/year, direct EPS impact $0.80-1.20/share
  • ◆Gross margin record at 50% is unsustainable: Lam guided 50-150bps tariff headwind; if China mix improves plus tariffs persist, GM reverts to 47-48%, reducing earnings $300-600M/year
Primary Debate on Wall Street

“Secular thesis (HBM creates structurally higher WFE floor, CSBG valued separately as recurring annuity, through-cycle EPS floor rising) vs. cyclical reversion (38x P/E prices 7-10 years above-trend growth, never happened in semcap history; first sign of AI capex moderation triggers simultaneous earnings + multiple compression). Debate resolves at Q4 FY2026 earnings (July 2026) when management sets FY2027 WFE guidance: ≥$140B validates secular; <$130B validates cyclical.”

Top Catalysts
  • ◆Q4 FY26 earnings + FY27 WFE guide (July 2026) — most important thesis validator, VERY HIGH magnitude
  • ◆HBM4 volume production confirmation from Samsung/SK Hynix (2H 2026) — validates supercycle thesis, HIGH magnitude
  • ◆Advanced packaging revenue +50% YoY confirmed (July 2026) — validates secular narrative, HIGH magnitude
  • ◆NAND ramp Korea/Japan (Q4 FY26 – Q1 FY27) — provides second growth engine, MEDIUM magnitude
  • ◆New BIS export restrictions to China (Any 2026-27) — permanent revenue loss, VERY HIGH downside magnitude
  • ◆AI capex pause signal from hyperscalers (Q3-Q4 2026) — falsifies HBM supercycle thesis, HIGH downside magnitude
Top Risks
  • ◆WFE cycle turns (MEDIUM-HIGH probability 50%, HIGH severity) — simultaneous earnings + multiple compression; only mitigation is CSBG floor providing trough support
  • ◆China BIS restrictions expand (MEDIUM probability 30%, HIGH severity) — permanent $2-3B revenue loss with no mitigation available
  • ◆AI capex moderation (LOW-MEDIUM probability 20%, HIGH severity) — demand diversification to NAND/advanced packaging provides partial offset
  • ◆AMAT/TEL wins HAR etch at Samsung (LOW probability 10%, MEDIUM severity) — switching cost moat thesis breaks if credible competitor qualification achieved
  • ◆Gross margin compression (MEDIUM probability 30%, MEDIUM severity) — tariff headwinds + China mix changes already embedded in guidance
  • ◆CEO Tim Archer departure (LOW probability 5%, MEDIUM severity) — strong operational bench reduces severity

Full Memo Continues

5 more sections, locked

  • ●
    Valuation Range & DCF
    Base/bull/bear fair-value range, WACC, terminal growth, sensitivity to revenue + margin assumptions.
  • ●
    Risk/Reward Assessment
    Position-sizing framework with explicit upside/downside skew and entry conditions.
  • ●
    Management & Capital Allocation
    Multi-year capital-allocation track record, incentive alignment, and management readout.
  • ●
    Monitoring Framework
    What to watch each quarter — leading indicators and inflection signals tracked by the analyst.
  • ●
    Unresolved Questions
    Open analyst questions and follow-up research items — the depth signal.

For Agents — $2 per memo

Call the JSON API with a Stripe Shared Payment Token. No account, no signup — just pay and call.

GET /api/v1/research/LRCX/memo
Authorization: Bearer spt_...

Fund managers — coverage subscriptions launching soon. See marginofinsight.com.

Margin of Insight

For informational purposes only. Not investment advice.